SEC For	m 4 FORM			CTA-			-C A1							SCION					
	UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549											551014		OMB APPROV					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).				TEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP	Estim		er: verage burde sponse:	3235-0287 n 0.5	
1. Name and Address of Reporting Person <sup>*</sup> Kaye Edward M. MD					2. Issuer Name <b>and</b> Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 03/27/2023									X Officer (give title below) Other (specify below) CEO					
45 WIGGINS AVENUE					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BEDFORD MA 01730														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication         Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	ole I - Non	-Deriv	ative Se	curities Ac	quire	d, D	isp	osed o	f, oi	r Bene	eficiall	y Owned	I				
Date						2A. Deemed Execution Date, if any (Month/Day/Yea	Cod	nsact de (Ins			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)					Form (D) o	vnership I: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								de V	/	Amount		(A) or (D)	Price	Transac	Transaction(s) (Instr. 3 and 4)			(11511. 4)	
Common Stock 03/27/								1		20,000		Α	\$0.6	45	,000	D			
						urities Acq s, warrants								Owned					
1. Title of Derivative Security (Instr. 3)	2. 3. Transaction Conversion or Exercise Price of Derivative Security		Date, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or	6. Date Exercisal Expiration Date (Month/Day/Year			of Securities			ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi (Instr. 4)		

(A) or Disposed of (D) (Instr. 3, 4 and 5) Reported Transaction(s) (Instr. 4) Amount or Number of Shares Date Exercisable Expiration Date v (D) Title (A) Code Employee Stock Option Common Stock \$<mark>0.6</mark> 03/27/2023 Μ 20,000 (1) 04/02/2028 20,000 \$0.00 602,801 D (right to buy)

Explanation of Responses:

1. The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

Remarks:

<u>/s/ Stephen Tulipano, Attorney-</u> 09/08/2023

\*\* Signature of Reporting Person Date

in-Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.